You are here

Study Evaluating Etanercept on Skin and Joint Disease in Psoriatic Arthritis

Last updated on May 11, 2018

FOR MORE INFORMATION
Study Location
Buenos Aires, , 1234 Argentina
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Psoriatic Arthritis
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18+ years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- 18 years of age or older at time of consent

- Active Psoriatic Arthritis

- Clinically stable, plaque psoriasis involving more than 10% of the body surface area

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Evidence of skin conditions other than psoriasis that would interfere with skin
examinations.

- Systemic anti-psoriasis therapy or DMARD within 28 days of study drug initiation

- Prior exposure to any TNF-inhibitor, including etanercept

NCT00245960
Pfizer
Completed
Study Evaluating Etanercept on Skin and Joint Disease in Psoriatic Arthritis

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.

Similar Trials

Systemic Lupus Erythematosus, Rheumatoid Arthritis
NCT03334851
All Genders
18+
Years
Multiple Sites
Hip Osteoarthritis, Knee Osteoarthritis
NCT02709486
All Genders
18+
Years
Multiple Sites
Study Evaluating Etanercept on Skin and Joint Disease in Psoriatic Arthritis
A Randomized, Double-Blind, Two-Period Study to Evaluate the Safety and Efficacy of Etanercept on Skin and Joint Disease in Psoriasis Subjects With Psoriatic Arthritis.
To assess the efficacy of two different treatment regimens of etanercept in psoriasis subjects with psoriatic arthritis with respect to both the skin and joint manifestations.
Not Provided
Interventional
Phase 4
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Psoriatic Arthritis
Drug: etanercept
Group A: Period 1: 50mg BIW. Period 2: 50 mg QW. Group B: Period 1 and 2: 50mg QW.
  • Active Comparator: A
    Intervention: Drug: etanercept
  • Active Comparator: B
    Intervention: Drug: etanercept


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
752
May 2008
May 2008   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • 18 years of age or older at time of consent
  • Active Psoriatic Arthritis
  • Clinically stable, plaque psoriasis involving more than 10% of the body surface area

Exclusion Criteria:

  • Evidence of skin conditions other than psoriasis that would interfere with skin examinations.
  • Systemic anti-psoriasis therapy or DMARD within 28 days of study drug initiation
  • Prior exposure to any TNF-inhibitor, including etanercept
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Argentina,   Australia,   Austria,   Belgium,   Czech Republic,   Denmark,   Finland,   France,   Germany,   Greece,   Hungary,   Italy,   Korea, Republic of,   Mexico,   Netherlands,   Poland,   Portugal,   Saudi Arabia,   Serbia,   Spain,   Sweden,   Switzerland,   Taiwan,   Turkey,   United Kingdom
Former Serbia and Montenegro
 
NCT00245960
0881A5-401
Not Provided
Not Provided
Not Provided
Wyeth (Registry Contact: Clinical Trial Registry Specialist), Wyeth
Wyeth is now a wholly owned subsidiary of Pfizer
Not Provided
Principal Investigator: Trial Manager For Argentina, [email protected] or [email protected]
Principal Investigator: Trial Manager For Belgium, [email protected]
Principal Investigator: Trial Manager For Denmark, Finland, Sweden, [email protected]
Principal Investigator: Trial Manager For Germany, [email protected]
Principal Investigator: Trial Manager For Greece, [email protected]
Principal Investigator: Trial Manger For Hungary, [email protected]
Principal Investigator: Trial Manager For Australia, Korea, Taiwan, [email protected]
Principal Investigator: Trial Manager For Mexico, [email protected]
Principal Investigator: Trial Manager For Netherlands, [email protected]
Principal Investigator: Trial Manager For Poland, [email protected]
Principal Investigator: Trial manager For Switzerland, [email protected]
Principal Investigator: Trial Manager For Turkey, [email protected]
Principal Investigator: Trial Manager For UK, [email protected]Â
Principal Investigator: Trial Manager For Austria, [email protected]
Principal Investigator: Trial Manager For Portugal,Saudi Arabia, [email protected]
Study Director: Medical Monitor Wyeth is now a wholly owned subsidiary of Pfizer
Principal Investigator: Trial Manager For France, [email protected]
Principal Investigator: Trial Manager For Italy, [email protected]
Principal Investigator: Trial Manager For Spain, [email protected]
Wyeth is now a wholly owned subsidiary of Pfizer
March 2009

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now